The Company has developed and is implementing proprietary methods and platform technologies to advance a broad, scalable, and combinable portfolio of injectable and oral NuSH analog peptides with the potential to address not only the limitations of approved therapies but also many of the anticipated limitations of next-generation therapies in development. The Company uses its proprietary MINT peptide library of NuSH analog peptides alongside its Half-life Augmentation by Lipid Optimization half-life extending platform.
We grade stocks based on past performance, their future growth potential, intrinsic value, dividend history, and overall financial health.
The chart below shows how we grade Metsera (MTSR) across the board compared to its closest peers.
Benzinga Edge stock rankings give you four critical scores to help you identify the strongest and weakest stocks to buy and sell.
See how Metsera compares to its peers in these key performance metrics from Benzinga Rankings.
Below, you can see that analysts are estimating a 12-month price target range of $50.00 - $77.00 with an average of $61.33
Recent Ratings for Metsera (MTSR)
The two main factors that we consider when analyzing past performance is overall return and volatility
Using these two metrics, we can determine if this stock gave its investors enough return for the risk that they took on by owning it. This is measured by the sharpe ratio, which has been used as a primary measure of risk/reward trade-off for almost 60 years.
This ratio can be interpreted as the amount of return an investor has received for the amount of risk that they took on by owning the stock over that timeframe.
Metsera (MTSR) sharpe ratio over the past 5 years is 0.8410 which is considered to be above average compared to the peer average of 0.5490
Based on our data, MTSR's options trades have recently carried more negative sentiment than positive.
